Skip to content

Contact Us
Careers

Contact Us
Careers

Company

TVAX Immunotherapy^®

TVI-Brain-1

Pipeline

Patient Resources

News

About TVAX Biomedical
Management
Board of Directors

About TVAX Biomedical
Management
Board of Directors

Manufacturing
Support References

Manufacturing
Support References

Additional Programs

Additional Programs

glioblastoma

TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study

Tvaxbio2 / October 18, 2022

OLATHE, Kan., Oct. 18, 2022 — TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study […]

TVAX Biomedical Receives Fast Track Designation from the FDA

Tvaxbio2 / April 30, 2020

Olathe, KS, April 30, 2020 – TVAX Biomedical today announced receipt of Fast Track Designation from the US Food and

TVAX Biomedical Names Wayne Carter as President and CEO

Tvaxbio2 / March 11, 2019

Olathe, KS, March 11, 2019 – TVAX Biomedical, a clinical stage development company advancing its proprietary T cell-based immunotherapy for

Revolutionizing Cancer Care, One Patient at a Time

About
Patient Resources
News
Pipeline

THE TVAX IMMUNOTHERAPY® PLATFORM
TVI-BRAIN-1
Careers
Contact Us

PRIVACY POLICY | TERMS OF USE

© 2024 - 2026 TVAX Biomedical, Inc. All Rights Reserved.

Scroll to Top